STMM yields 3333.33% · JNJ yields 2.13%● Live data
📍 STMM pulled ahead of the other in Year 1
Combined, STMM + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of STMM + JNJ for your $10,000?
Stemcell Holdings, Inc., through its subsidiary, Stemcell Co., Ltd., engages in the regenerative medicine-related business. It provides technical assistance services to the culturing, storing, and delivery of stem cells; and administrative and consulting services to clinics. The company offers two different options for stem cell regenerative therapy, including autologous adipose derived mesenchymal stem cells and natural killer cells. It also provides coordination services to facilitate its stem cell culturing business, which comprise the introduction of patients to clinics, arranging patients' schedules, and translating between patients and clinics due to language barriers. In addition, Stemcell Holdings, Inc. offers Internet marketing services through search engine optimization for clinics; and property and equipment rental services. The company was formerly known as Perfect Acquisition, Inc., and changed its name to Stemcell Holdings, Inc. in January 2016. Stemcell Holdings, Inc. was founded in 2015 and is based in Tokyo, Japan. as of May 2, 2016, Stemcell Holdings, Inc. operates as a subsidiary of Primavera Singa Pte Ltd.
Full STMM Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.